The Power of the Microbiome in the Fight Against Disease
What if we could leverage the impact of the gut microbiome on the human immune system to fight one of the most devastating diseases we face today? Persephone Biosciences, a resident company of JLABS @ San Diego, is combining artificial intelligence with population-scale patient data with the aim to develop ground-breaking microbial cell therapies to treat cancer. We’re bringing together Dirk Gevers, Global Head, Microbiome Solutions, World Without Disease Accelerator at Janssen R&D and Stephanie Culler, CEO of Persephone Biosciences to dive into their technology platform and its potential impact on cancer, as well as their recently developed candidate for an immune-boosting microbiome therapeutic aimed to help prevent and fight SARS-CoV-2.
About The Microbiome Solutions group:
微生物组解决方案组is focused on accelerating the translation of today’s promising microbiome science into tomorrow’s health solutions. The group believes that fostering cooperation and partnerships within the scientific, medical and entrepreneurial communities will be essential to effectively translate promising microbiome science into solutions that address the root cause of disease and promote health. The group combines its pioneering expertise in the microbiome with the drug discovery, product development and commercialization know-how of a leading global biopharmaceutical company. This team was previously recognized as the Janssen Human Microbiome Institute (JHMI)
About Persephone Biosciences:
Persephone Biosciencestakes a novel approach to improving the efficacy of existing therapies, leveraging the systemic impact of the gut microbiome on the human immune system. Persephone's technology platform is based on collecting and analyzing gut microbiota samples from thousands of patients, then using machine learning in conjunction with systems biology tools to understand the impact of gut microbes on patient prognosis. The results are used to design novel immunotherapies and companion diagnostics for unmet needs. Persephone's lead therapeutic candidate is planned to enter clinical trials in late 2020.
The information on this webpage, including in the videos, is proprietary or licensed to Johnson & Johnson Innovation LLC, its parent company or any affiliate companies (“JJI”) and is for informational purposes only. This content is not intended to influence the use, sale, recommendation, or promotion of any products or services of Johnson & Johnson or its affiliates. The information presented in the videos is specific and applicable to region in which the original presentation took place. Many videos contain information from, or sessions given by, third parties. Please note that only those third parties that provide this information are responsible for it. By providing this information, JJI does not endorse these third parties or any of the information provided in these videos, and JJI makes no representations, warranties, or assurances, express or implied, as to the content or the information presented and is not responsible for any use of this information by you.
